Vi ønsker å komme i kontakt med medlemmer som har innspill til hvordan man kan legge til rette for enklere tilgang og bedre utnyttelse av helsedata.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 323 entries.
Entries by oslocancer
Nordic Nanovector enters collaboration with Heidelberg Pharma GmbH to develop antobody drug conjugates for treating leukaemias.
RealKarriere is the Career Day for the The Faculty of Mathematics and Natural Sciences at University in Oslo. In 2017 the Career day will be arranged on February 9th 2017.
Kreftkostnader i Norge: Hvor ligger de største kostnadene? Hvilken kreftform er dyrest? Oslo Economics har utarbeidet en rapport om kostnadene ved kreft.
NCGC is joining forces with Norwegian Cancer Registry to establish a research platform for tumor-profiling in recruiting patients for clinical trials. They would like the help form members of the Oslo Cancer Cluster on what targets to include in the gene panel,
The Research Council is planning to announce up to NOK 45 million in funding for projects that promote value creation in the healthcare industry and is organising an applicant’s workshop on 24. October.
Nordic Nanovector ASA, is pleased to announce it has entered into a collaboration with LegoChem Biosciences, Inc. , a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias.
December 15th is the date for the annual DNB HealthCare Conference. Be sure to apply for both the Health Care prize and to be a part of the Venture Session.
Over 50 people turned up for our R&D Network meeting on Precision Cancer Medicin at Stavanger University Hospital yesterday. The meeting was a collaboration beetween Oslo Cancer Cluster and Stavanger University Hospital(SUS) and was hosted by SUS.
Since IBM became a member of Oslo Cancer Cluster in June this year there has been a tremendous interest in their robot, Watson. The role of cognitive technology in cancer diagnostics has received attention both in national and international media.
Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference in the frequency or grade of adverse events in patients having one Blue Light Cystoscopy with Cysview® (BLCC) versus repeat BLCC procedures.
Early September Oslo Cancer Cluster hosted an international press event with our member Abbvie. Over 20 journalists from all over Europe came to the Oslo Cancer Cluster Incubator and Innovatiion Park to learn more about the latest technological and scientific developments within cancer research. The journalists attended a full day meeting at the Innovation […]
The Nordic Life Science Days 2016 was a great success at many levels. For the first time the Norwegian life science actors invited to a joint meeting to promote a closer collaboration with the Swedish life science milieu at an event at the Norwegian Embassy in Stockholm.
Leading oncology biopharmaceutical company BerGenBio AS, today released important new preclinical study data on its first-in-class AXL inhibitor, BGB324.
Vicepresident Joe Biden used Norway as an example when he spoke at the Social Good Summit this week. Biden was appointed by Barack Obama to lead the “Cancer Moonshot” project. The project aims to make a decade’s worth of advances in cancer prevention, diagnosis, treatment, and care in just 5 years.
Artemida Pharma and Arctic Pharma are now members of the Oslo Cancer Cluster. Please find more information on the new members below. Arctic Pharma is also part of the Oslo Cancer Cluster Incubator.
Ketil Widerberg was interviewed alongside Jason Paragas from the Lawrence Livermore Research Laborator about the role of cooperation and supercomputers in finding breakthroughs in cancer prevention and treatment. You can see the interview here (in english) (forward to 16:47)
Photocure ASA announced today that data from the OPTIC III study: Optimized photodynamic diagnosis for transurethral resection of the bladder tumor (TURBT) in German clinical practice, is now available online in the World Journal of Urology. For more information see here.
PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company reported today an update on the phase I/II study in inoperable bile duct cancer patients.
Nordic Nanovector ASA (OSE: NANO) announces that two papers recently published in The Journal of Nuclear Medicine have shown that pre-dosing with the anti-CD37 antibody lilotomab (previously referred to as HH1), prior to injection with Betalutin® (177Lu-lilotomab) reduces haematological toxicity without adversely impacting the amount of radiation absorbed by the tumour.
Oslo Cancer Cluster member PCI Biotech is a cancer focused biopharmaceutical company. They have initiated a preclinical agreement with BioNTech AG which is a fully integrated biotechnology company developing individualized cancer immunotherapies.
5 students from Ullern High School do an intership at the Department of Molecular Pathology
On Wednesday 12th October 2016, the Netherlands Enterprise Agency, together with the EUREKA Secretariat and Enterprise Europe Network are organising an international event dedicated to the Eurostars programme (www.eurostars-eureka.eu) at the Amsterdam Arena in Amsterdam, the Netherlands.
Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project this spring. The official kick-off for the project is September 7th to 8th in Karlsrue and project manager Gupta Udatha is hired to work in both Oslo and Halden to implement the project from Norwegian side.
Inven2 has received NOK 6 mill from Innovation Norway to support Norwegian start-ups.
Oslo, Norway, August 29, 2016, Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer.
Det overordnede målet med Innovasjonsrammen 2016 er å stimulere til økt innovasjon gjennom flere felles innovasjons- og forskningsprosjekter mellom bedrifter.
Kreftvaksineselskapet Ultimovacs AS henter NOK 75 millioner til finansiering av videre kliniske studier. Selskapet har gjennomført tre vellykkede fase I-studier for sin terapeutiske vaksine mot kreft. Over 50 kreftpasienter har deltatt i studiene. Studiene viser at mer enn 80% av pasientene får aktivert sitt immunsystem som følge av denne behandlingen.
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin® have been completed.
New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product
Oslo Cancer Cluster member PCI Biotech has received positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin.
The International Journal of Cancer has recently published preclinical in vivo data in a mesothelioma xenograph model, demonstrating synergy of ONCOS-102 with pemetrexed and cisplatin, the current standard of care in malignant pleural mesothelioma.
Helseforskere kan få støtte til deltagelse i Horisont 2020 søknader fra to nye utlysninger:
Oslo 1 July 2016: Targovax today announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.
Nordic Nanovector, a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, announced today that they have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need. Prevalent relapsed AML and CLL patients are more than 60,000 per year worldwide. This represents a growing market worth over USD 5 billion by 2020.
The Oslo Cancer Cluster Incubator has recruited Nadine Lohs to be responsible for the operation of the Incubator from 1st August.
I sterk konkurranse fra 45 søkere har Inven2 fått tildelt NOK 6 mill av presåkornpotten for 2016 fra Innovasjon Norge.
Forskningsrådet har publisert utlysning av midler til postdoktor på kreftområdet med søknadsfrist 7. september 2016. Postdoktorperioden er totalt 3 år, hvorav de to første årene ved IARC i Lyon, Frankrike, og det siste året ved den norske søkerinstitusjonen.
EUs SMB-instrument i Horisont 2020 støtter testing og verifisering av disruptive innovasjoner. Meld deg på kurs hos Innovasjon Norge 16. juni i Oslo for å lære om hva du skal tenke på for å best beskrive din prosjektide og markedsplan i en søknad.
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology announces that Luigi Costa, Chief Executive Officer, will hold a presentation at BIO International Convention in San Francisco, US on Tuesday 7 June 2016, at 3:30pm PDT in the room: Theater 1.
Targovax receives approval to conduct a study with TG02 and pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS mutated rectal cancer.
Erlend Strønen, Johanna Olweus and the Immunotherapy Jebsen Center team’s work on a breakthrough methodological development in generating broad and tumour-specific T-cell immune responses has been published in Science. The work is based on a novel allogeneic approach. This is a powerful technological development which can in the relatively near future be subjected to clinical testing.
Nordic Nanovector reports steady operational progress on Betalutin®’s clinical development plan in Follicular Lymphoma (FL), with recruitment of both sites and patients proceeding according to schedule. The Lymrit 37-01 study is on track to define the optimized dose regimen to be used in PARADIGME, the pivotal Phase 2 study planned to start in 2H 2017. Updated data from this ongoing clinical study, presented at the American Association of Cancer Research (AACR) in April, confirm Betalutin®’s efficacy potential, durability of response and favourable safety profile in patients with advanced FL.
Photocure ASA announced today new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview® increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone.
Nordic Nanovector ASA announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin®.
The Norwegian Society for Immunology hosted their annual conference on the Day of Immunology on April 29. The theme for 2016 was Immunotherapy for Cancer. Below you may download some of the presentations as a courtesy of the lecturers.
Photocure ASA announced today the American Urological Association (AUA) and the Society of Urological Oncology (SUO) have included enhanced cystoscopy in the 2016 Guidelines for the management of non-muscle invasive bladder cancer (NMIBC).
Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at OUS have been funded by the Future and Emerging Technology (FET) program. The program funded 11 projects out of 820 grant applications, and the proposal by Theodossiou and Berg was rated as number 6.
The DoMore! project aims to explore the unique combination of academic and industrial competence within the project group to radically improve prognostication and hence treatment of cancer by using digital tools for pathology.
Photocure ASA is pleased to announce publication of a new analysis demonstrating that Blue Light Cystoscopy (BLC) with Hexvix/Cysview significantly prolonged time to disease progression and showed a trend in the reduction of the rate of progression in patients with non-muscle invasive bladder cancer (NMIBC). The data was published online in the April issue of the peer reviewed journal, Bladder Cancer.
Oslo Cancer Cluster will for the 5th time arrange International Cancer Cluster Showcase, ICCS in collaboration with leading cluster partners from Europe and North America. 20 oncology biotechs will pitch their latest innovations and partnering opportunities.
BerGenBio AS with preclinical data demonstrating that lead compound, BGB324, combined with immune checkpoint inhibitors has the potential to synergistically improve treatment of human cancers.
Nordic Nanovector with updated results of its ongoing Phase 1/2 study with Betalutin® in relapsed non-Hodgkin lymphoma (NHL) patients. Betalutin® was generally well tolerated and showed a 63.2% Overall Response Rate (ORR) including 31.6% Complete Response (CR) among 21 patients with previously treated CD37+ NHL patients.
Targovax has conducted an interim DTH immunological response evaluation assessing early immune activation following administration of TG01 in combination with gemcitabine in the ongoing Phase I/II trial. The results show that the modified and reduced vaccination schedule generated similar 8-week immune responses in patients with pancreatic cancer, as seen in the initial cohort.
The Immuno-Oncology Educational Series 2016 on April 6th featured cutting-edge presentations from leading Finnish and Norwegian clinicians and researchers within the field of cancer immunotherapy.
Nordic Nanovector ASA announces it has entered into a research and development collaboration programme with Paul Scherrer Institute (PSI) in Switzerland.
Institute for Energy Technology – IFE and ONLY Oncology are now members of the Oslo Cancer Cluster.
Cevira® is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix.
-Vi er svært overrasket og skuffet over dagens beslutning om at norske pasienter ikke får tilgang til den nyeste brystkreftmedisinen som allerede er i bruk i de fleste vesteuropeiske land. Roche harstrukket seg langt, både økonomisk og i variasjon av betalingsløsninger, sier kommunikasjonsdirektør Line Walen i Roche Norge.
The EU project will use innovative IT solutions to develop personalized cancer treatment. The EU project will use innovative IT solutions to develop personalized cancer treatment. Allocated funds is 45 million, of which 34 million is earmarked for small and medium enterprises in the clusters.
The interim results indicate promising 1-year overall survival data when combining TG01 with gemcitabine, chemotherapy, as supplementary treatment of patients with pancreatic cancer.
Taskén, who is director of the Biotechnology Centre and the Norwegian Centre for Molecular Medicine (NCMM), receives the award for his work with immunotherapy.
Vaccibody AS announced on March 1 the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16).
Oslo Cancer Cluster member Photocure had a great year in 2015 with increased sales. Photocure is a Norwegian specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, listed on the Oslo Stock Exchange.
Nordic Nanovector ASA announces that a late-breaking abstract on its Phase 1/2 clinical study with Betalutin® has been accepted for presentation at the American Association For Cancer Research (AACR) annual meeting.
Curida strengthens its Development Services with a strategic partnership with Dr. René Bommer, who is known for his competency within Nasal Spray and chairs the annual Nasal Drug Delivery conference.
The coverage includes an overview of the cancer treatment being developed by 10 of Oslo Cancer Cluster member companies.
På Verdens kreftdag 4. februar retter Kreftforeningen, Oslo Cancer Cluster og Kreftregisteret søkelyset mot den tause folkesykdommen tarmkreft. Tarmkreftscreening kan redde livet til 300 nordmenn årlig. Det er tre ganger så mange som dør i trafikken hvert år.
The Norwegian Research Council granted Oslo Cancer Cluster member companies Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector funding through the Programme for User-Driven Research Based Innovation (BIA).
Nordic Nanovector receive prestigious BIA funding to support the research and development of novel targeted therapeutics for leukemia and non-Hodgkin Lymphoma.
Oslo Cancer Cluster member and therapeutic vaccine company Vaccibody has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program.
Cancer Crosslinks 2016 featured very interesting, cutting-edge presentations from some of the leading cancer clinicians and researchers in the US and Norway. You may download them here or watch some as videos.
The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies.
PCI Biotech reports that the treatment evaluation of the fourth dose cohort in the Phase I/II study of fimaporfin (Amphinex®) in patients with inoperable bile duct cancer has been completed.
Serviceproduksjon is a subsidary to the Norwegian Pharmace Association. The agreement entails validation of a chemical analytical method for use in analysis of tablets.
Oslo Cancer Cluster had a tremendous growth in the number of members in 2015: 14 new ones joined us. In total the cluster now comprise of 75 members. Please find a short description of our new members from 2015 below.
Cancer Crosslinks 2016 features a really interesting program. For those of you that may not take part of the actual conference in the Oslo Cancer Cluster Innovation Park, you may watch the whole program at your computer as we will live stream from beginning to end.
Oslo Cancer Cluster member Smartfish recently presented that juices containing omega-3, whey proteins and natural antioxidants have beneficial effects on body weight, muscle weight and tumour size in a mouse model for cancer cachexia with or without concomitant chemotherapy.
Thermo Fisher Scientific will rent over 800m2 in the Oslo Cancer Cluster Incubator. Here, the company will create a creative Google-like environment with a particular focus on diagnostics and the development of new treatments using cancer immunotherapy.
Cancer Crosslinks 2016 on January 14 features a really strong program with several renowned international speakers whom have played a major role in developing immunotherapies against cancer. Sign up now.
Oslo Cancer Cluster member Sarsia Seed and Tromsø-based Norinnova have been given the managment of two new national seed capital funds on MNOK 300 in total by the Norwegian government. The money will be matched by privat capital.
The venture session at the DNB Healthcare Conference features three Oslo Cancer Cluster member companies: Lytix Biopharma, Vaccibody and Regencis. They will all present in session five: Therapeutics, that starts at 15:00.
Of the six nominated for the DNB HealthCare Prize on 1 MNOK, two of them are members of the Oslo Cancer Cluster: Vaccibody and Ultimovacs. The other nominees are: Spiro Medical, Glucoset, Picterus and Labrida.
Ludwig Cancer Research and the Cancer Research Institute (CRI) initiate agreement with Oslo Cancer Cluster member Targovax to evaluate its experimental virotherapy, ONCOS-102, in early phase clinical trials.
HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.
On November 11 Oslo Cancer Cluster, BMS and MSD arranged the second meeting in the Immuno-Oncology Meeting Series of 2015. You may download the presentations here.
According to The European Biotech News Website, Oslo Cancer Cluster Incubator is the hottest bioincubator in the Nordics as well as the 6th hottest in Europe.
DNB Health Care Conference on December 15th features many of Oslo Cancer Cluster member companies. There will also be a parallel venture session, organised by DNB together with Oslo Medtech, Oslo Cancer Cluster and Nansen Neuro.
February 9th 2016 is the date for the annual Career Day VIVO at NTNU for biology-, chemistry- and biotech students at bachelor and masters.
Centre for Cancer Biomarkers (CCBIO) is a Centre of Excellence at the Faculty of Medicine and Dentistry, University of Bergen. Read their latest news.
February 18 2016 is the date for the annual Career Day at the University of Oslo for students at the Natural Sciences Faculties. Please see more info below.
På vegne av Det Norske Videnskaps-Akademi har vi gleden av å invitere til åpent debattmøte om helseprioriteringer i fremtiden 26. oktober kl 18:15 – 20:00, i Auditoriet på Litteraturhuset i Bergen, Østre Skostredet 5-7. Med bakgrunn i Prioriteringsutvalgets rapport vil debattantene debattere prioriteringer av de begrensede ressursene i norsk helsevesen. Deltagere: Ole Frithjof Norheim, leder […]
January 26.2016 is the date for the annual Career Day at NTNU. Please see more info below on this.
The Minister of Finance Siv Jensen, and the Minister of Trade and Industry, Monica Mæland will be present at the opening to launch a new plan for Norwegian entrepreneurship.
4 Oslo Cancer Cluster member companies will pitch at Norwegian Investment Forum during Oslo Innovation Week Thursday October 15th: Vaccibody, Nordic Nanovector, Regenics and Phoenix Soloutions.
Oslo Cancer Cluster has analyzed the budget in relation to sectors that concern our members.
Åpen innovasjon brer om seg. Hva har det å si for helsevesenet og for de klynger og bedrifter som skaper morgendagens legemidler, helseteknologi og tjenester? Få med deg Open Health Innovation Arena 12. oktober.
The study will investigate the use of Hexvix/Cysview in the outpatient / surveillance setting and is designed to fulfill the FDA post marketing commitments.
DNB Healtcare gives out an Healtcare Award on 1MNOK to Healtcare start-ups.
Oslo Cancer Cluster member Nextera has entered into a research agreement with Janssen Biotech, Inc.
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.